NCT00399828终止4 期
Clinical Study For Evaluation Of The Efficacy and Safety Of Tri-ActiveTM (Deka M.E.L.A., Itália) In Treatment Of Cellulite
Hexsel Dermatology Clinic0 个研究点目标入组 20 人开始时间: 2006年8月1日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 发起方
- 入组人数
- 20
- 主要终点
- Assessment of effectiveness of treatment based on current classification of cellulite and evaluation corporal measures
研究概览
简要总结
The purpose of this study is to assess the efficacy of device TRI-ACTIVETM (DEKA M.E.L.A., Itália)in the treatment od cellulite and body contouring.
详细描述
The present study is a clinical, opened trial and single-center.
The patients will be treated by six laser diodes, localised cooling system and rhythmical intake massage device. Application of the massage will be performed for 8 weeks in a total of 16 treatment sessions: twice a week.
A set of photographs will be taken at visit 1 (baseline), visit 2 and 3 with standardized positions and lighting conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Written Informed Consent;
- •Subjects agreeing to take part of all procedures of the study (including mechanical massage, photographs), after being fully informed on the objectives and nature of the investigations;
- •Female subjects between 18-45 years;
- •Subjects presenting with cellulite grades I-III on buttocks and thighs;
- •Medical history and physical examination which, based on the investigator's opinion, do not prevent the patient from taking part in the study and use the device under investigation;
- •Female subjects of childbearing age should present a negative urine pregnancy test and should be using an effective contraceptive method (3 months before the enrollement untill the end of the study);
- •Body Mass Index (BMI = weight/height2) beetwen 20,0-25,0;
- •Availability of the subject throughout the duration of the study (60 days);
- •Availability of the subject in maintaining a stable weight during the study (variation less than 2 kg)
- •Subjects with sufficient schooling and awareness to enable them to cooperate to the degree required by this protocol.
排除标准
- •Pregnant women or women intending to become pregnant during the study (next 3 months);
- •BMI superior 25,0;
- •Subjects with diabetes mellitus, cardiac insufficiency, asthma, or bronchitis;
- •Subjects participating in other clinical trials;
- •Subjects with neoplastic disorders, uncontrolled thyroid disorders or uncontrolled hypertension;
- •Subjects with coagulation disorders, using anticoagulants or tendency of bruises;
- •Subjects with vascular disorders (phlebitis or varicose veins) in the area to be treated;
- •Any prior aesthetic surgery affecting the area to be treated (liposuction, Subcision®), 3 months before the study, that may interfere with results;
- •Any other prior anti-cellulite treatment or body measures treatment, 30 days prior to the study;
- •Subjects with inflammation or active infection in the area to be treated.
- •Subjects with a history of adverse effects, which in the investigator's opinion should prevent the patient from participating in the study;
- •Patients with cutaneous or vascular alterations, that difficult visualization and documentation of cellulite;
- •Subjects with a history of medical treatment non-adherence or showing unwillingness to adhere to the study protocol;
- •Subjects who can not come to the visits (one missing visit/ month is allowed);
- •Subjects intending to initiate any intensive sport;
- •Subjects using analgesics, non-hormonal antiinflammatories, antihistaminics, corticosteroids, or diuretics;
- •Subjects tanned, or intending to expose the area of study to sun, artificial UV, or self-tanning during the study;
- •Any condition that, in the opinion of the investigator, can compromise the evaluation of the study.
结局指标
主要结局
Assessment of effectiveness of treatment based on current classification of cellulite and evaluation corporal measures
次要结局
- Assessment of subject's satisfaction
- Visual assessments of the treated area before and after treatment
- Safety analysis
研究者
相似试验
终止
2 期
Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine TreatmentMetastatic Breast CancerAdvanced Breast CancerNCT00452140Neovii Biotech40
已完成
3 期
Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD)Attention Deficit Hyperactivity Disorder (ADHD)NCT03260205Shire199
已完成
不适用
Observational Study of Triple Combination Therapy of Zemidapa Tab. and Metformin in Type 2 Diabetes Mellitus PatientsType 2 Diabetes MellitusNCT06495281LG Chem2,044
招募中
3 期
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingNCT06408259Bristol-Myers Squibb194
已完成
不适用
Clinical study on the effectiveness of three products in the treatment of herpes simplex labialisB00.1Herpesviral vesicular dermatitisDRKS00007786Sylphar NV180